Adnan Malik, Mahum Nadeem, Waseem Amjad, Muhammad Imran Malik, Sadia Javaid, Umer Farooq, Khadija Naseem, Ahmad Khan
{"title":"Aramchol对非酒精性脂肪肝(NAFLD)患者的影响。系统回顾和荟萃分析。","authors":"Adnan Malik, Mahum Nadeem, Waseem Amjad, Muhammad Imran Malik, Sadia Javaid, Umer Farooq, Khadija Naseem, Ahmad Khan","doi":"10.5114/pg.2022.113573","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nonalcoholic fatty liver disease (NAFLD) comprises a wide range of related liver disorders affecting mainly people who drink no or very little alcohol. Aramchol is a new synthetic molecule that has been shown to reduce liver fat content. There is little evidence supporting its efficacy in humans.</p><p><strong>Aim: </strong>To evaluate the efficacy of Aramchol in patients with NAFLD according to different randomized clinical trials.</p><p><strong>Material and methods: </strong>We searched PubMed, SCOPUS, Web of Science, and Cochrane Library for relevant clinical trials assessing the use of Aramchol in patients with NAFLD. Risk of bias assessment was performed using Cochrane's risk of bias tool. We included the following outcomes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), glycated haemoglobin (HbA<sub>1c</sub>), total cholesterol (TC), triglyceride (TG), HOMA-IR, and insulin level.</p><p><strong>Results: </strong>We included 3 clinical trials. We found that the Aramchol group did not show any significant difference from the control group regarding ALT (MD = 3.92 (-21.20, 29.04), <i>p</i> = 0.76), AP (MD = -0.59 (-8.85, 7.67), <i>p</i> = 0.89), HbA<sub>1c</sub> (MD = -0.11 (-0.32, 0.10), <i>p</i> = 0.29), TC (MD = 14.25 (-626, 34.77), <i>p</i> = 0.17), TG (MD = 2.29 (-39.30, 43.87), <i>p</i> = 0.91), HOMA-IR (MD = -0.11 (-1.58, 1.37), <i>p</i> = 0.89), and insulin levels (MD = -0.88 (-5.82, 4.06), <i>p</i> = 0.73). AST levels were significantly higher in the Aramchol group (MD =11.04 (4.91, 17.16), <i>p</i> = 0.04).</p><p><strong>Conclusions: </strong>Aramchol was a safe and tolerable drug to be used in patients with NAFLD. However, it was not superior to placebo in reducing the biochemical liver markers.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"18 1","pages":"67-75"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/1b/PG-18-46420.PMC10050975.pdf","citationCount":"1","resultStr":"{\"title\":\"Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis.\",\"authors\":\"Adnan Malik, Mahum Nadeem, Waseem Amjad, Muhammad Imran Malik, Sadia Javaid, Umer Farooq, Khadija Naseem, Ahmad Khan\",\"doi\":\"10.5114/pg.2022.113573\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Nonalcoholic fatty liver disease (NAFLD) comprises a wide range of related liver disorders affecting mainly people who drink no or very little alcohol. Aramchol is a new synthetic molecule that has been shown to reduce liver fat content. There is little evidence supporting its efficacy in humans.</p><p><strong>Aim: </strong>To evaluate the efficacy of Aramchol in patients with NAFLD according to different randomized clinical trials.</p><p><strong>Material and methods: </strong>We searched PubMed, SCOPUS, Web of Science, and Cochrane Library for relevant clinical trials assessing the use of Aramchol in patients with NAFLD. Risk of bias assessment was performed using Cochrane's risk of bias tool. We included the following outcomes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), glycated haemoglobin (HbA<sub>1c</sub>), total cholesterol (TC), triglyceride (TG), HOMA-IR, and insulin level.</p><p><strong>Results: </strong>We included 3 clinical trials. We found that the Aramchol group did not show any significant difference from the control group regarding ALT (MD = 3.92 (-21.20, 29.04), <i>p</i> = 0.76), AP (MD = -0.59 (-8.85, 7.67), <i>p</i> = 0.89), HbA<sub>1c</sub> (MD = -0.11 (-0.32, 0.10), <i>p</i> = 0.29), TC (MD = 14.25 (-626, 34.77), <i>p</i> = 0.17), TG (MD = 2.29 (-39.30, 43.87), <i>p</i> = 0.91), HOMA-IR (MD = -0.11 (-1.58, 1.37), <i>p</i> = 0.89), and insulin levels (MD = -0.88 (-5.82, 4.06), <i>p</i> = 0.73). AST levels were significantly higher in the Aramchol group (MD =11.04 (4.91, 17.16), <i>p</i> = 0.04).</p><p><strong>Conclusions: </strong>Aramchol was a safe and tolerable drug to be used in patients with NAFLD. However, it was not superior to placebo in reducing the biochemical liver markers.</p>\",\"PeriodicalId\":20719,\"journal\":{\"name\":\"Przegla̜d Gastroenterologiczny\",\"volume\":\"18 1\",\"pages\":\"67-75\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/1b/PG-18-46420.PMC10050975.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Przegla̜d Gastroenterologiczny\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pg.2022.113573\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2022.113573","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 1
摘要
非酒精性脂肪性肝病(NAFLD)包括广泛的相关肝脏疾病，主要影响不饮酒或很少饮酒的人。芳烃是一种新的合成分子，已被证明可以减少肝脏脂肪含量。几乎没有证据支持它对人类有效。目的:通过不同的随机临床试验，评价芳香醇治疗NAFLD的疗效。材料和方法:我们检索PubMed、SCOPUS、Web of Science和Cochrane Library以获取评估Aramchol在NAFLD患者中使用的相关临床试验。采用Cochrane偏倚风险评估工具进行偏倚风险评估。我们纳入了以下结果:丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(AP)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、甘油三酯(TG)、HOMA-IR和胰岛素水平。结果:我们纳入了3项临床试验。我们发现Aramchol组与对照组没有任何明显的区别对于ALT (MD = 3.92 (-21.20, 29.04), p = 0.76),美联社(MD = -0.59 (-8.85, 7.67), p = 0.89),糖化血红蛋白(MD = -0.11 (-0.32, 0.10), p = 0.29), TC (MD = 14.25 (-626, 34.77), p = 0.17), TG (MD = 2.29 (-39.30, 43.87), p = 0.91), HOMA-IR (MD = -0.11 (-1.58, 1.37), p = 0.89),和胰岛素水平(MD = -0.88 (-5.82, 4.06), p = 0.73)。Aramchol组AST水平显著高于对照组(MD =11.04 (4.91, 17.16)， p = 0.04)。结论:Aramchol是一种安全、耐受的药物，可用于NAFLD患者。然而，在降低肝脏生化指标方面，它并不优于安慰剂。
Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis.
Introduction: Nonalcoholic fatty liver disease (NAFLD) comprises a wide range of related liver disorders affecting mainly people who drink no or very little alcohol. Aramchol is a new synthetic molecule that has been shown to reduce liver fat content. There is little evidence supporting its efficacy in humans.
Aim: To evaluate the efficacy of Aramchol in patients with NAFLD according to different randomized clinical trials.
Material and methods: We searched PubMed, SCOPUS, Web of Science, and Cochrane Library for relevant clinical trials assessing the use of Aramchol in patients with NAFLD. Risk of bias assessment was performed using Cochrane's risk of bias tool. We included the following outcomes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), glycated haemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), HOMA-IR, and insulin level.
Results: We included 3 clinical trials. We found that the Aramchol group did not show any significant difference from the control group regarding ALT (MD = 3.92 (-21.20, 29.04), p = 0.76), AP (MD = -0.59 (-8.85, 7.67), p = 0.89), HbA1c (MD = -0.11 (-0.32, 0.10), p = 0.29), TC (MD = 14.25 (-626, 34.77), p = 0.17), TG (MD = 2.29 (-39.30, 43.87), p = 0.91), HOMA-IR (MD = -0.11 (-1.58, 1.37), p = 0.89), and insulin levels (MD = -0.88 (-5.82, 4.06), p = 0.73). AST levels were significantly higher in the Aramchol group (MD =11.04 (4.91, 17.16), p = 0.04).
Conclusions: Aramchol was a safe and tolerable drug to be used in patients with NAFLD. However, it was not superior to placebo in reducing the biochemical liver markers.
期刊介绍：
Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
